FUJIFILM Toyama Chemical
As of the edition of 20 October 2026, FUJIFILM Toyama Chemical runs 6 drugs, 5 of them marketed; it is on route A at 0 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 1 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lutetium oxodotreotide | Ends 2031 (exclusivity) | 10 |
| Arginine | none listed | 0 |
| Favipiravir | none listed | 0 |
| Iobenguane | none listed | 2 |
| Lysine | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 6 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where FUJIFILM Toyama Chemical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mental health: 3 trials led
- Nervous system: 2 trials led